marked.bio

Company

Exelixis

3 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

zanzalintinib 2atezolizumab 2regorafenib 1olaparib 1avelumab 1

Trials

3 of 3 trials shown

  1. Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

    Active, not recruiting Phase 3 Exelixis Started 2022Primary completion 2026-06 NCT05425940

    zanzalintinibatezolizumab FDAregorafenib

    Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.

    MSI-H / dMMRColorectal Cancer

  2. A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

    Recruiting Phase 1 Exelixis Started 2024Primary completion 2029-01 NCT05932862

    XL309olaparib FDA EU

    …R2)-negative breast cancer, with deleterious or suspected deleterious breast cancer gene (BRCA)1/2 alteration.

    BRCA1/2 mutationAdvanced Solid Tumor

  3. A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

    Active, not recruiting Phase 1 Exelixis Started 2019Primary completion 2026-08 NCT03845166

    zanzalintinibatezolizumab FDAavelumab

    BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations

    BRAF V600EMSI-H / dMMRNeoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer